Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease

Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Journal of Clinical and Experimental Neuropsychology (Impact Factor: 2.08). 02/2010; 32(7):775-9. DOI: 10.1080/13803390903521018
Source: PubMed


While little is known about risk factors for cognitive impairment in early onset Parkinson disease (EOPD), postmortem studies have shown an association between dementia with Lewy bodies (DLB) and glucocerebrosidase (GBA) mutation. We compared Mini-Mental State Examination (MMSE) performance and self-reported cognitive impairment in 699 EOPD participants genotyped for mutations in parkin (PRKN), leucine-rich repeat kinase-2 (LRRK2), and GBA. Logistic regression was used to assess the association between reported cognitive impairment and MMSE score, as well as between GBA group membership and self-reported impairment and MMSE. GBA carriers reported more impairment, but MMSE performance did not differ among genetic groups. Detailed neuropsychological testing is required to explore the association between cognitive impairment and GBA mutations.

Download full-text


Available from: Susan Mickel, Oct 05, 2015
18 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper presents experimental studies of a carbon-fiber emitter-array Using commercial carbon-fiber products, we built a carbon-fiber emitter-array gun. The gun consists of two accelerating stages to produce a long-pulse electron-beam array. It demonstrated ~400 μs pulses of ~0.1 A in each channel with this configuration. The gun was used in the carbon-fiber CRM-array experiment successfully
    Vacuum Electronics Conference, 2000. Abstracts. International; 02/2000
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The cognitive profile of early onset Parkinson's disease (EOPD) has not been clearly defined. Mutations in the parkin gene are the most common genetic risk factor for EOPD and may offer information about the neuropsychological pattern of performance in both symptomatic and asymptomatic mutation carriers. EOPD probands and their first-degree relatives who did not have Parkinson's disease (PD) were genotyped for mutations in the parkin gene and administered a comprehensive neuropsychological battery. Performance was compared between EOPD probands with (N = 43) and without (N = 52) parkin mutations. The same neuropsychological battery was administered to 217 first-degree relatives to assess neuropsychological function in individuals who carry parkin mutations but do not have PD. No significant differences in neuropsychological test performance were found between parkin carrier and noncarrier probands. Performance also did not differ between EOPD noncarriers and carrier subgroups (i.e., heterozygotes, compound heterozygotes/homozygotes). Similarly, no differences were found among unaffected family members across genotypes. Mean neuropsychological test performance was within normal range in all probands and relatives. Carriers of parkin mutations, whether or not they have PD, do not perform differently on neuropsychological measures as compared to noncarriers. The cognitive functioning of parkin carriers over time warrants further study.
    Journal of the International Neuropsychological Society 01/2011; 17(1):91-100. DOI:10.1017/S1355617710001190 · 2.96 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Synucleopathies are neurodegenerative disorders characterized by abnormal accumulation of alpha-synuclein, most often in neurons. Familial forms are due to mutations or multiplications of the gene encoding for alpha-synuclein but most synucleopathies occur sporadically. They include Parkinson's disease (PD) and dementia with Lewy Bodies (DLB), which are both linked to cognitive decline. In DLB, dementia dominates the symptoms whereas in PD, subtle cognitive deficits are frequent and may appear even before motor symptoms, but only a fraction of patients develop severe dementia-type cognitive deficits. Several lines of mice were developed to model human synucleopathies by over-expressing the wild type or the mutated human alpha-synuclein under a variety of promoters. In addition, mice lacking alpha-synuclein have been used to determine the role of this protein in cognitive function. This chapter will review cognitive alterations observed in these models and discuss how they may help understand the various forms and stages of cognitive deficits observed in patients with synucleopathies.
    01/2011; 1(3):217-27. DOI:10.3233/JPD-2011-11043
Show more